Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumors
In brief
The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of GS-2121 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.
Key facts
- Study ID
- NCT06532565
- Run by
- Gilead Sciences
- People needed
- 154
- Starts
- 2024-07-26
- Expected to finish
- 2028-06-01
- Last updated by the study team
- 2026-04-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford Cancer Center — Palo Alto, California, United States (enrolling)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
- NEXT Oncology — San Antonio, Texas, United States (enrolling)
- NEXT Virginia — Fairfax, Virginia, United States (enrolling)
- The Ottawa Hospital Cancer Centre — Ottawa, Canada (enrolling)
- Princess Margaret Cancer Centre — Toronto, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.